Drug Development Core

项目摘要/摘要 药物开发核心(DDC)通过以下方式直接支持UWCCC开发创新疗法的使命 提供经济高效、尖端、高通量的筛查(HTS)服务；药物化学和铅 优化服务；以及支持临床试验的药代动力学(PK)和药效学(PD)服务。 这些服务得到了广泛的专业知识、最先进的设备和尖端技术的支持 用于分析设计、合成化学、计算化学、分析化学和 药理学。通过一套以任务为中心的具体目标，DDC将实现对 UWCCC成员。具体目标1：通过提供以下服务促进UWCCC成员的药物开发研究 化合物发现、药物化学、计算化学和 化学预防和抗癌药物的药理学。具体目标1主要目标是提供 充分支持UWCCC用户所需的专业知识、设备和计算工具。具体来说，DDC 工作人员将就实验设计、数据获取和数据分析提供建议，以确保实验的严密性和可重复性 以具有成本效益的方式进行高影响力的药物开发研究。影响：13项HTS活动，10项专利，以及 10条毒品线索。具体目标2：通过提供专业知识和支持在UWCCC进行的临床试验 评估研究药物的药代动力学和药效学特性所需的基础设施。 为了达到这一目标，数据中心将为患者样本存储提供一个强大和安全的数据库系统，以 记录所有样品。此外，DDC将提供分析专业知识，以适当地采样、分析和 对患者组织中的药物和药物代谢物进行量化。这些服务对于UWCCC参与 NCI赞助的UM1计划、NCI的国家临床试验网络(NCTN)和行业赞助的临床 审判。在目前的资助期内，社区发展中心资助了394项UWCCC研究，其中包括209项NCI研究 赞助的研究。鉴于发展治疗计划提议扩大临床试验， 我们预计，在下一个资金阶段，这一数字将会增加。具体目标3：培训UWCCC成员，其 工作人员和学生在药物开发过程和最先进设备的生产性使用中 以满足他们的研究目标。经验丰富的DDC员工将确保设备得到很好的维护， 高度可靠，并为UWCCC成员、他们的工作人员和学生提供全天候服务。此外， DDC工作人员将定期向PI、博士后和实习生介绍研究成果和新技术。DDC有 在当前资助期内，培训了168多名与UWCCC有关的用户。通过这些特定的 AIMS，DDC不仅将支持UWCCC的使命，还将为UWCCC成员提供直接支持 以最大限度地发挥其影响，并进一步推进前沿癌症研究。DDC支持109个独特的UWCCC 2017-2021年期间，UWCCC所有6个科学计划和113个成员出版物的计划成员。

PROJECT SUMMARY / ABSTRACT The Drug Development Core (DDC) directly supports the UWCCC mission to develop innovative therapies by providing cost-effective, cutting-edge, high-throughput screening (HTS) services; medicinal chemistry and lead optimization services; and pharmacokinetic (PK) and pharmacodynamic (PD) services to support clinical trials. These services are supported by extensive expertise, state-of-the-art equipment, and cutting-edge computational tools for assay design, synthetic chemistry, computational chemistry, analytical chemistry, and pharmacology. Through a mission-centered set of specific aims, the DDC will achieve a high level of support for UWCCC members. Specific Aim 1: Advance UWCCC member drug development research by providing expertise and resources for compound discovery, medicinal chemistry, computational chemistry, and pharmacology of chemoprevention and anticancer agents. The primary goal of Specific Aim 1 is to provide the expertise, equipment, and computational tools required to fully enable UWCCC users. Specifically, the DDC staff will advise on experimental design, data acquisition, and data analysis to ensure rigor and reproducibility of high impact drug development research in a cost-effective manner. Impact: 13 HTS campaigns, 10 patents, and 10 drug leads. Specific Aim 2: Support clinical trials conducted at UWCCC by providing the expertise and infrastructure needed to evaluate the pharmacokinetic and pharmacodynamic properties of study drugs. To achieve this aim, the DDC will provide patient sample storage with a robust and secure database system to document all samples. Additionally, the DDC will provide analytical expertise to properly sample, analyze, and quantify drugs and drug metabolites from patient tissues. These services are critical to UWCCC participation in NCI sponsored UM1 programs, NCI’s National Clinical Trials Network (NCTN), and industry sponsored clinical trials. In the current funding period, the DDC provided support for 394 UWCCC studies including 209 NCI sponsored studies. Given the proposed expansion of clinical trials by the Developmental Therapeutics program, we predict this number to increase in the next funding period. Specific Aim 3: Train UWCCC members, their staff, and students in drug development processes and the productive use of state-of-the-art equipment to meet their research goals. The highly experienced DDC staff will ensure that equipment is well maintained, highly reliable, and available for UWCCC members, their staff, and students on a 24/7 basis. Additionally, the DDC staff will routinely present studies and new technologies to PI’s, postdocs, and trainees. The DDC has trained over 168 users associated with the UWCCC during the current funding period. Through these Specific Aims, DDC will not only support the mission of the UWCCC but also provide direct support to UWCCC members to maximize their impact and further advance cutting-edge cancer research. DDC supported 109 unique UWCCC program members across all 6 UWCCC scientific programs and 113 member publications during 2017-2021.